XNAS
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -1.67 | -3.54 | -111.98% | $0 | ❌ Miss | +3.18% | +13.27% | — |
| 2026-03-19 | Q4 2025 | -6.77 | -26.06 | -284.93% | $0 | ❌ Miss | +0.00% | +17.96% | +17.48% |
| 2025-11-13 |
| Q3 2025 |
| -0.22 |
| -0.68 |
| -209.09% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.16 | -0.49 | -206.25% | $0 | ❌ Miss | -3.32% | -9.97% | -43.21% |
| 2025-03-21 | Q4 2024 | -1.33 | -0.37 | +72.18% | $0 | ✅ Beat | -2.75% | -4.59% | -12.83% |
| 2024-11-08 | Q3 2024 | -2.44 | -2.85 | -16.80% | $0 | ❌ Miss | -1.57% | +6.27% | +1.18% |
| 2024-08-14 | Q2 2024 | -2.31 | -1.70 | +26.41% | $0 | ✅ Beat | -10.80% | +1.80% | -2.80% |
| 2024-05-10 | Q1 2024 | -3.53 | -2.02 | +42.78% | $0 | ✅ Beat | -1.89% | +6.72% | -9.45% |
Showing last 8 quarters.